Proactive Investors - Run By Investors For Investors

Smith & Nephew on track to deliver full-year guidance as third-quarter revenue rises thanks to strong demand in US, emerging markets

In a brief trading update, the FTSE 100-listed medical technology group said its third-quarter revenue was US$1.169bn, up 2% on a reported basis and 3% on an underlying basis
Knees
S&N forecast that its 2018 underlying revenue would be in the lower half of the 2% to 3% range

Smith & Nephew PLC (LON:SN.) shares rose on Thursday after the medical technology firm said it is on track to deliver in its full-year guidance as it reported solid growth in third-quarter revenue thanks to strong demand in the US and emerging markets.

In a brief trading update, the FTSE 100-listed group said its third-quarter revenue was US$1.169bn, up 2% on a reported basis and 3% on an underlying basis.

READ: New Smith & Nephew boss gives bullish assessment of artificial hip maker’s health

The firm said quarterly underlying revenue growth was 4% in the US and 10% in emerging markets.

The artificial knees and hips maker forecast that its 2018 underlying revenue would be in the lower half of the 2% to 3% guidance range, but said it expected its trading profit margin to be above last year's thanks to improved cost controls and a favourable legal settlement.

Namal Nawana, S&N’s recently appointed chief executive officer, said: "These results were achieved whilst successfully redesigning how we will run the company. There is still more to do, and I am pleased with the pace of progress and engagement across the organisation."

Hips and knees growth

In a note to clients, analysts at UBS commented: “Both Hips & Knee growth was 4% underlying, in line with the acceleration management expected but ahead of cons in our view.

“However weakness in Europe and Wound Bioactives (-7%) means that management now guides to the bottom end of the previous range of 2-3% underlying revenue growth.”

They added: “Investors are looking for cost control, but revenue guidance may be a focus.”

UBS reiterated a ‘neutral’ stance and 1,340p per share 12-month price target on Smith & Nephew.

In late morning trading in London, the bluechip stock was 6.7% higher at 1,359p.

 -- Adds analyst comment, share price --

View full SNN profile View Profile

Smith & Nephew PLC Timeline

Related Articles

A doctor's stethoscope and a marijuana plant
February 22 2019
With top-line data from the CONNECT-FX trial on the way, investors are eying the opportunity defined by marijuana-adjacent companies like Zynerba Pharmaceuticals
lung in x-ray
February 25 2019
The company has been developing a treatment for chronic lung disease in-house and has partnered with an Australian group to develop a drug for rare liver and lung complaints
Once the phase III trial is completed, Futura plans to either sell off the asset or find a partner
September 26 2018
The pharma group expects to dose the first patient in the Phase III trial of its MED2002 erectile dysfunction treatment within the next month

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use